FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549	
-------------	------------	--

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Keyt Bruce (Last) (First) (Middle) C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD (Street) MOUNTAIN VIEW CA 94043						2. Issuer Name and Ticker or Trading Symbol IGM Biosciences, Inc. [IGMS] 3. Date of Earliest Transaction (Month/Day/Year) 05/24/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)											5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Scientific Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(St	ate) (Z	Zip)																				
		Table	I - Non	-Deriva	tive \$	Secui	rities	Acq	quir	red, C	Dis	posed	of, o	r B	enefici	ally	Own	ed					
1. Title of Security (Instr. 3)				ansaction th/Day/Yea	r) Ex	2A. Deemed Execution I if any (Month/Day		Co	Transaction Code (Instr.		4. Securities Acq Disposed Of (D) (5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Co	ode	de V		ount	(A) or (D)	N) or Price		Reporte Transa (Instr. 3		tion(s)					
Common Stock				05/24/2022				S	S ⁽¹⁾			939	D	D \$17.10		15 ⁽²⁾		39,489		D			
Common Stock																	1,013		I		See footnote ⁽³⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	4. Transa Code 8)	(Instr.	5. Nur of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5)	ative ities red sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date				Ar Se Ur De Se	nour ecurit nderl erivat ecurit and 4	lying itive ity (Instr.	1		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		

Explanation of Responses:

- 1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
- 2. This transaction was executed in multiple trades at prices ranging from \$16.79 to \$17.1269. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- 3. The shares are held directly by the reporting person's spouse.

Remarks:

/s/ Misbah Tahir, by power of atto<u>rney</u>

05/26/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.